Cisplatin

Overview

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions

Advanced Ovarian Cancer
Ovarian Cancer Metastatic
Advanced Bladder cancer
Advanced Testicular cancer
Metastatic Testicular cancer

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study	2025/07/31	NCT07097142	Not Applicable	Not yet recruiting	NRG Oncology
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma	2025/07/22	NCT07076212	Not Applicable	Not yet recruiting	Medical University of South Carolina
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer	2025/07/22	NCT07078604	Not Applicable	Not yet recruiting	University of Washington
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion	2025/07/14	NCT07063745	Not Applicable	Not yet recruiting	Bristol-Myers Squibb
Induction Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer	2025/07/14	NCT07061977	Not Applicable	Not yet recruiting	National Cancer Institute (NCI)
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	2025/06/29	NCT07043400	Not Applicable	Not yet recruiting	BeiGene
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma	2025/06/26	NCT07039162	Phase 2	Not yet recruiting	Ming-Yu Lien
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC	2025/06/18	NCT07026474	Phase 3	Not yet recruiting	Universität des Saarlandes
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer	2025/06/17	NCT07025174	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer	2025/06/05	NCT07005336	Phase 2	Recruiting	TJ Biopharma Co., Ltd.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
CISPLATIN	FOSUN PHARMA USA INC	72266-253	INTRAVENOUS	1 mg in 1 mL	8/4/2023
CISplatin	Apotex Corp.	60505-6277	INTRAVENOUS	50 mg in 50 mL	12/21/2023
CISPLATIN	Gland Pharma Limited	68083-163	INTRAVENOUS	1 mg in 1 mL	9/26/2023
CISplatin	WG Critical Care, LLC	44567-509	INTRAVENOUS	1 mg in 1 mL	9/16/2021
Cisplatin	Teva Parenteral Medicines, Inc.	0703-5747	INTRAVENOUS	50 mg in 50 mL	8/30/2022
CISPLATIN	Gland Pharma Limited	68083-162	INTRAVENOUS	1 mg in 1 mL	9/26/2023
Cisplatin	Sagent Pharmaceuticals	25021-253	INTRAVENOUS	1 mg in 1 mL	6/29/2023
CISplatin	WG Critical Care, LLC	44567-511	INTRAVENOUS	1 mg in 1 mL	9/16/2021
CISPLATIN	BluePoint Laboratories	68001-608	INTRAVENOUS	1 mg in 1 mL	12/18/2023
CISPLATIN	BluePoint Laboratories	68001-609	INTRAVENOUS	1 mg in 1 mL	12/18/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
DBL CISPLATIN INJECTION 1 mg/ml	HOSPIRA AUSTRALIA PTY LTD	SIN00762P	INJECTION	1 mg/ml	5/4/1988
CISPLATIN INJECTION 1 mg/ml	PFIZER (PERTH) PTY LTD	SIN05418P	INJECTION	1 mg/ml	2/18/1991

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
SINPLATIN CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/10ML	N/A	TEVA PHARMACEUTICAL HONG KONG LIMITED	N/A	N/A	8/25/2011
SINPLATIN CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/50ML	N/A	TEVA PHARMACEUTICAL HONG KONG LIMITED	N/A	N/A	8/18/2011

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
DBL CISPLATIN 50mg/50mL Injection	47275	Pfizer Australia Pty Ltd	Medicine	A	1/31/1994
Hospira Cisplatin 50mg/50ml Concentrate for Infusion vial	159984	Hospira Australia Pty Ltd	Medicine	A	3/10/2009
Cisplatin Injection 50 mg/50 mL (9)	407210	Pfizer (Perth) Pty Ltd	Medicine	A	4/3/2023
DBL CISPLATIN 100mg/100mL Injection	47276	Pfizer Australia Pty Ltd	Medicine	A	1/31/1994
Cisplatin Injection 100 mg/100 mL (1)	283858	Pfizer (Perth) Pty Ltd	Medicine	A	12/20/2016
Cisplatin Injection 10 mg/10 mL (10)	406414	Pfizer (Perth) Pty Ltd	Medicine	A	3/20/2023
Cisplatin Injection 100 mg/100 mL (3)	407211	Pfizer (Perth) Pty Ltd	Medicine	A	4/3/2023
Hospira Cisplatin Injection 1 mg/mL, 50 mg/50 mL Onco-Tain vial	462455	Hospira Australia Pty Ltd	Medicine	A	9/20/2024
Hospira DBL Cisplatin Injection 50 mg in 50 mL vial	374895	Hospira Australia Pty Ltd	Medicine	A	9/20/2021
Cisplatin Sterile Concentrate Injection 50 mg/50 mL oncotain	138860	Hospira Australia Pty Ltd	Medicine	A	5/18/2007

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
PLATINOL AQ INJ 1MG/ML	bristol labs division of bristol-myers squibb	00788740	Liquid - Intravenous	1 MG / ML	12/31/1988
CISPLATIN INJ 0.5MG/ML	david bull laboratories (pty) ltd.	00644293	Liquid - Intravenous	.5 MG / ML	12/31/1985
CISPLATIN INJECTION, MYLAN STD.	Mylan Pharmaceuticals ULC	02396890	Solution - Intravenous	1 MG / ML	6/12/2013
CISPLATIN INJECTION	Strides Pharma Canada Inc	02393832	Solution - Intravenous	1 MG / ML	N/A
CISPLATIN INJECTION BP	hikma canada limited	02536285	Solution - Intravenous	1 MG / ML	2/23/2024
CISPLATIN INJ 1MG/ML	david bull laboratories (pty) ltd.	00692743	Liquid - Intravenous	1 MG / ML	12/31/1986
PMS-CISPLATIN	Pharmascience Inc	02409194	Solution - Intravenous	1 MG / ML	N/A
CISPLATIN INJECTION	omega laboratories limited	02422034	Solution - Intravenous	1 MG / ML	N/A
CISPLATIN INJECTION	teva canada limited	02403188	Solution - Intravenous	1.0 MG / ML	8/29/2013
CISPLATIN INJECTION, BP	Accord Healthcare Inc	02355183	Solution - Intravenous	1 MG / ML	4/10/2012

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
CISPLATINO ACCORD 1 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSION EFG	Accord Healthcare S.L.U.	72609	CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN	Uso Hospitalario	Commercialized
CISPLATINO PHARMACIA 1 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSION EFG	Pharmacia Nostrum S.A.	62107	CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN	Uso Hospitalario	Commercialized
PLATICEPT 50 MG POLVO PARA SOLUCION INYECTABLE EFG	Pharmacept Gmbh	81365	LIOFILIZADO PARA SOLUCIÓN INYECTABLE	Uso Hospitalario	Not Commercialized
CISPLATINO HIKMA 1 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG	Hikma Farmaceutica (Portugal) S.A.	86466	CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN	Uso Hospitalario	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Targeted Therapies Transform Biliary Tract Cancer Treatment Landscape with FGFR2 Inhibitors Leading Clinical Advances

20 days ago

Biliary tract cancer treatment has evolved from traditional cytotoxic chemotherapy to include targeted therapies based on specific molecular alterations, with FGFR2 inhibitors showing particularly promising results.

FDA Approves Retifanlimab Plus Carboplatin/Paclitaxel for Advanced Anal Cancer Following PODIUM-303 Trial Success

21 days ago

The FDA approved retifanlimab in combination with carboplatin/paclitaxel for advanced anal cancer in May 2025, based on the PODIUM-303 study results.

Atezolizumab Shows Consistent Efficacy in Cervical Cancer Regardless of PD-L1 Status, BEATcc Trial Analysis Reveals

a month ago

A post hoc analysis of the phase 3 BEATcc trial demonstrates that atezolizumab combined with chemotherapy and bevacizumab provides consistent clinical benefits in cervical cancer patients irrespective of PD-L1 expression levels.

Toripalimab Emerges as Preferred PD-1 Inhibitor for Metastatic Nasopharyngeal Carcinoma Despite Access Challenges

2 months ago

Toripalimab has received NCCN category 1 recommendation for nasopharyngeal carcinoma based on positive phase 3 data in both first-line and second-line settings, unlike pembrolizumab which showed negative results in the KEYNOTE-122 trial.

Ferroptosis Emerges as Novel Therapeutic Target in Cancer Treatment and Immunotherapy